Compare Live Nation Entertainment, Inc. (LYV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs ResMed Inc. — how do they compare? Live Nation Entertainment, Inc. trades at $176.52 (market cap $42.09B), while ResMed Inc. trades at $196.27 (market cap $28.81B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.21% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | RMD | |
|---|---|---|
Market Cap | $42.09B | $28.81B |
Sector | Industrials | Health |
52-Week High | $186.59 | $293.73 |
52-Week Low | $125.61 | $182.82 |
Enterprise Value | $43.59B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation (LYV) trades at $180.84, up 0.34% today, with bullish technical signals from moving averages despite recent earnings misses. The company reported $25.2B revenue for 2025 with a slim 0.33% net margin, while valuation metrics show elevated P/E (117.49) and P/B (136.72) ratios. Recent news highlights executive share sales and ongoing legal scrutiny, though analyst consensus remains strongly bullish with an $200.20 price target.
Outlook remains mixed with strong revenue growth potential from concert demand and ticketing margins offset by profitability challenges and legal overhangs. The stock offers upside to analyst targets but faces execution risks amid high valuations and recent earnings volatility.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
